Drug contamination test maker Rapid Micro secures $60M in financing to expand

woman with back to camera working in a laboratory
Rapid Micro Biosystems secured $60 million in financing to expand its microbial detection technology for drug manufacturers. (Michal Jarmoluk)

Rapid Micro Biosystems, maker of microbial detection technology for drug manufacturers, secured $60 million in financing to expand its global reach and develop new products.

The equity financing was led by Bain Capital Life Sciences and Xeraya Capital. Also included in the funding round were Asahi Kasei Medical, Longitude Capital, Quaker Partners, TVM Capital, and Richard K. Mellon and Sons.

Massachusetts-based Rapid Micro focuses on technology to detect microbial contamination in the manufacturing of pharmaceuticals, biologics, biotechnology products, medical devices and personal care products.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Its Growth Direct technology is a growth-based system that automatically detects contamination, helping reduce costs for drug manufacturers while increasing the quality control process, the company said. By quickly detecting microbial contamination, drug manufacturers can reduce inventory carrying costs, shorten manufacturing cycles and reduce product losses.

“The new round of investment will fuel significant business growth and strategic capability that will strengthen our ability to serve customers globally,” Robert Spignesi, Rapid Micro’s CEO, said in a statement.

Last year, Boston-based Bain teamed with the London-based private equity firm of Cinven to buy German drugmaker Stada in a $5.63 billion deal.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.